Impact of previous COVID-19 on immune response after a single dose of BNT162b2 SARS-CoV-2 vaccine

Velasco, María; Galín, I; Casas, Luisa; Pérez‐Fernández, Elia; Martínez-Ponce, Diana; González-Piñeiro, Beatriz; Castilla,; Guijarro, Carlos

doi:10.1101/2021.03.08.21253065

Cited by 7 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The geometric mean of spike IgG after the second injection was 17378 AU/mL, which was higher than corresponding values measured in a naïve Spanish COVID-19 population, 12 but similar to another study. 13 In addition, the range of values was quite broad, from 2826 AU/mL to 70272 AU/mL.…”

Section: Discussionsupporting

confidence: 84%

Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?

Takeuchi

Higa

Esaki

et al. 2021

Preprint

View full text Add to dashboard Cite

Adverse reactions are more common after the second injection of messenger RNA vaccines such as Pfizer/BioNTech's BNT162b2. We hypothesized that the degree and severity of reactogenicity after the second injection reflects the magnitude of antibody production against the SARS CoV-2 virus spike protein (spike IgG). Blood samples were obtained from 67 healthy Japanese healthcare workers three weeks after the first injection and two weeks after the second injection of the BNT162b2 vaccine to measure spike IgG levels. Using questionnaires, we calculated an adverse event (AE) score (0-11) for each participant. The geometric mean of spike IgG titers increased from 1,047 antibody units (AU/mL) (95% CI: 855±1282 AU/mL) after the first injection to 17,378 AU/mL (14,622±20,663 AU/mL) after the second injection. The median AE score increased from 2 to 5. Spike IgG levels after the second injection were negatively correlated with age and positively correlated with spike IgG after the first injection. AE scores after the second injection were not significantly associated with log-transformed spike IgG after the second injection, when adjusted for age, sex, and log-transformed spike IgG after the first injection. Although the sample size was relatively small, reactogenicity after the second injection may not accurately reflect antibody production.

show abstract

Section: Discussionsupporting

confidence: 84%

Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?

Takeuchi

Higa

Esaki

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…By Poisson model regression analysis, the reduced incidence among HCW adjusting for the background changes in the general population remained statistically and clinically significant: 3% reduction (IRR 0.272; 95% CI 0.164-0.451 p<0.001) after the first dose of the vaccine and 92 % (IRR 0.176, 95% CI 0.033-0.174; p<0.001) after the second dose (Supplemental Tables and Figure). It is conceivable that the response to the vaccine among HCW may have been boosted by a previous exposure to the virus [12,13]. .…”

Section: Resultsmentioning

confidence: 99%

“…Our results after a single dose of the vaccine might not be extrapolated to other settings: our vaccination program was extended to all HCW, including HCW with previous SARS-COV-2 documented infection [7]. We and others have recently shown that HCW with a previous SARS-CoV-2 infection exhibit a strong serologic response to the first dose of the vaccine, reaching higher IgG anti spike titre than that obtained after full vaccination in SARS-CoV-2 naïve individuals [12,13]. Other vaccination programs (excluding previously infected HCW) may exhibit a lower protection [2].…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 new infections among health care workers after the first dose of the BNT162b2 mRNA Covid-19 Vaccine

Guijarro

Galán²,

Martínez-Ponce³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Objectives. To evaluate the effect of mRNA SARS-Cov-2 vaccination on the incidence of new SARS-CoV-2 infections in health care workers (HCW). Methods. The evolution of the incident rate of SARS-CoV-2 infection in a cohort of 2590 HCW after a mRNA SARS-CoV-2 vaccination, as compared to the rate in the community (n=170513). SARS-CoV-2 infections were microbiologically confirmed by an antigen, a CRP positive test, or both. Results. A total of 1820 HCW (70,3% of total) received the first dose of the vaccine between January 10-16, 2021), and 296 (11,4%) the following week. All of them completed vaccination 3 weeks later. New SARS-COV-2 infections in HCW declined by 62% at 2-4 weeks after the first dose of mRNA SARS-CoV-2 vaccination and virtually disappeared after the second dose of the vaccine. Vaccination rate was negligible for this time period in the community (<5%). The decline in the incident rate of SARS-COoV-2 new infection in HCW shortly after the administration of the first dose of the vaccine was strikingly higher than the reduction observed in the general population (p<0.001and became even more pronounced after the second dose of the vaccine (p<0.001). Conclusions. mRNA SARS-CoV-2 vaccination is associated with a dramatic decline in new SARS-CoV-2 infection among HCW, even before the administration of the second dose of the vaccine.

show abstract

“…Unfortunately, the values cannot be comparatively evaluated because data obtained using Abbot-Quant® methodology, although expressed as BAU/mL, are in general lower than those reported by Roche-Elecsys® [18] . Lastly, even though published information on immunogenicity after full-dose vaccine administration is still limited and occasional, some experimental results from the literature as regards to the immune response after the second dose of BNT162b2 vaccine in a homologous schedule were evaluated [18] , [23] , [24] , [25] , [26] , [27] , [28] . The required conditions for the comparative study of VORs data were identical methodology (Abbott-Quant®) and exact time point for blood sampling (±1 day).…”

Section: Discussionmentioning

confidence: 99%

Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy

Raposo

Lippi

2021

Clinica Chimica Acta

View full text Add to dashboard Cite

Background Measurement of anti-SARS-CoV-2 RBD Ig G antibody response is very important to define the dynamics of immunization in vaccine COVID-19 recipients. Materials and methods Sera from four BNT162b2 vaccine recipients who erroneously received vaccine overdose were analyzed at different time-points. Results At 6 days the serum increase of antibodies was analogous for the three SARS-CoV-2 naïve recipients. At 14 days the antibody level increased and reached a peak, though showing a different pattern among the three recipients. At 21 days the serum antibody level started to decrease from its maximum value. The data for the previously infected recipient were in agreement with values found in COVID-19 positive receivers. Thus, after the single prime-dose of vaccine, the elicited antibody response was similar to prime-boost vaccination in naïve recipients. Conclusions In spite of the overdosage, this study confirms the efficiency of the BNT162b vaccine in eliciting a sustained antibody response as heterologous boost-vaccine in previously Oxford/AstraZeneca vaccinated recipients, as well as, prime-vaccine in COVID-19 infected receivers. Importantly, the humoral immune response of recipients was not proportional to the vaccine overdose. Nonetheless, we cannot portray a univocal effect of vaccine overdose concerning anti-SARS-CoV-2 antibody response because the values found were highly heterogeneous.

show abstract

Impact of previous COVID-19 on immune response after a single dose of BNT162b2 SARS-CoV-2 vaccine

Cited by 7 publications

References 11 publications

Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?

Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?

SARS-CoV-2 new infections among health care workers after the first dose of the BNT162b2 mRNA Covid-19 Vaccine

Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy

Contact Info

Product

Resources

About